Serum resistin is associated with C-reactive protein and LDL-cholesterol in type 2 diabetes and coronary artery disease in a Saudi population

Cardiovascular Diabetology

Volumn 4, Issue , 2005, Pages

  Al Daghri, N ^a   Chetty, R ^b   McTernan, P G ^d   Al Rubean, K ^c   Al Attas, O ^a   Jones, A F ^b   Kumar, Sudhesh ^d  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

C reactive protein; Coronary Artery disease; Resistin; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SAUDI ARABIA; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; MIDDLE AGED; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY ARTERY DISEASE; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; REGRESSION ANALYSIS; RESISTIN; SAUDI ARABIA;

EID: 26844576354     PISSN: 14752840     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-4-10     Document Type: Article

References (34)

1. Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27(3):813-23.
2. Dandona PA, Aljada, et al.: Inflammation: the lind between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25(1):4-7.
3. Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S53-5.
4. Nuamah MA, Yura S, Sagawa N, Itoh H, Mise H, Korita D, kakui k, Takemura M, Ogawa Y, Nakao K, Fujii S: Significant increase in maternal plasma leptin concentration in induce delivery: a possible contribution of pro-inflammatory cytokines to placental leptin secretion. Endocr J 2004, 51(2):177-87.
5. Sitaraman S, Liu X, Charrier L, Gu LH, Ziegler TR, Gewirtz A, Merlin D: Colonic leptin: source of a novel proinflammatory cytokine involved in IBD. FASEB J 2004, 18(6):696-8. Epub 2004 Feb 20.
6. Gaetke LM, Oz HS, Frederich RC, McClain CJ: Anti-TNF-alpha antibody normalizes serum leptin in IL-2 deficient mice. J Am Coll Nutr 2003, 22(5):415-20.
7. Rajala MW, Scherer PE: Minireview: The adipocyte at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003, 144(9):3765-73.
8. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, et al.: FIZZI, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines new gene family. Embo J 2000, 19(15):4046-55.
9. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al.: The hormone resistin links obesity to diabetes. Nature 2001, 409(6818):307-12.
10. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM: Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002, 10(1):1-5.
11. Ternan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S: Resistin, central obesity, and type 2 diabetes. Lancet 2002, 359(9300):46-7.
12. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al.: Resistin is expressed in human macrophages and directly regulated by PPARagnna activators. Biochem Biophys Res Commun 2003, 300(2):472-6.
13. Donovan JA, Koretzky GA: CD45 and the immune response. J Am Soc Nephrol 1993, 4(4):976-85.
14. Gomez-Ambrosi J, Fruhbeck G: Do resistin and resistin-linke molecules also link obesity to inflammatory diseases? Ann Intern Med 2001, 135(4):306-7.
15. Villena JA, Kim KH, Sul HS: Pref-1 and ADSF/resistin: two secreted factors inhibiting adipose tissue development. Horm Metab Res 2002, 34(11-12):664-7.
16. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Waston W, Kerr K, Jones R, Zhu Q, Considine RV: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88(11):5452-5.
17. Heilbronn LK, Rood J, et al.: Relationship between serum resistin concentration and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004, 89(4):1844-8.
18. Mc Ternan PG, Fisher FM, et al.: Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003, 88(12):6098-106.
19. Volarova de courten B, Degawa-Yamauchi M, Considin RV, Tatarnni PA: High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indian. Diabetes 2004, 53(5):1279-84.
20. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Eatrada E, Seip R, Orlova C, Mantzoros CS: Circulating resistin levels are not associated with obesity or insulin resistance in humans and not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin EndocrinolMetab 2003, 88(10):4848-56.
21. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, Kawahara Y, Yamazaki M, Ogata M, Hasegawa G, Nakamura N, Yoshikawa T, Nakano K, Ohta M: Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 2004, 339(1-2):57-63.
22. Valsamakis G, Mc Ternan PG, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AH, Kumar S: Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004, 53(4):430-4.
23. Wilson PW: Assessing coronary heart disease risk with traditional and novel risk factors. Clin Cardiol 2004, 27(6 Suppl 3):III7-11.
24. Mather HM, Keen H: The South all Diabetes Survey: prevalence of known diabetes in Asians and Europeans. Br Med J 1985, 291:1081-1084.
25. Jaber LA, Slaughter RL, Grunberger G: Diabetes and related metabolic risk factors among Arab Americans. Ann Pharmacother 1995, 29(6):573-6.
26. Kadiki OA, Roaded RB: Epidemiological and clinical patterns of diabetes mellitus in Benghazi, Libyan Arab Jamahiriya. East Mediterr Health J 1999, 5(1):6-13.
27. Abdella NA, Khogali MM, Salman AD, Ghuneimi SA, Bajaj JS: Pattern of non-insulin dependent diabetes mellitus in Kuwait. Diabetes Res Clin Pract 1995, 29(2):129-36.
28. McNeely MJ, Boyko EJ: Type 2 diabetes prevalence in Asian Americans: results of a national health survey. Diabetes Care 2004, 27(1):66-9.
29. Bajaj M, Banerji MA: Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian-Indian epidemic. Curr Diab Rep 2004, 4(3):213-8.
30. Matthews DRHJ, Rudenski AS, Naylor BA, Treacher DF, Turner RL: Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412-419.
31. Maachi M, Pieroni L, Bruckert E, Jardel C, Fellahi S, Hainque B, Capeau J, Bastard JP: Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord. 2004 Jun 22
32. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA: Abnormal Glucose Homeostasis due to Chronic Hyperresistinemia. Diabetes in press. 2004 Jun 9
33. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ: Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlation with insulin resistance. Eur J Endocrinol 2003, 149(4):331-5.
34. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T: Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003, 11(8):997-1001